Biodelivery: We Remain On The Sidelines Pending A Few More Weeks Of Bunavail Prescriptions, Say Roth Capital
Roth Capital analyst Scott Henry maintained a Neutral rating on Biodelivery Sciences (NASDAQ:BDSI) with a $20 price target, which represents a potential upside of 34% from where the stock is currently trading.
Henry wrote, “We publish our updated model post the quarterly results, the 10-Q filing, and the first week of Bunavail prescriptions. Our bias is positive, but we remain on the sidelines pending a few more weeks of Bunavail prescriptions to gauge the trend line. We do note a high probability of positive pipeline catalysts for the end of 2014 and early 2015.”
The analyst added, “We remain on the sidelines pending a few more weeks to determine the launch trajectory of Bunavail. Although our price target represents material upside, we believe that the risk remains elevated during the launch period, particularly post the strong run up in the share price over the past year.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Scott Henry has a total average return of 10.3% and a 43.1% success rate. Henry has a 25.8% average return when recommending BDSI, and is ranked #506 out of 3385 analysts.